LONDON-- GlaxoSmithKline PLC (GSK.LN), a pharmaceutical and healthcare company, said Friday it has set July 20 for expiration of tender offer to acquire Human Genome Sciences.

MAIN FACTS:

-Expiration is after HGS process bid deadline of July 16.

-Enables HGS shareholders to evaluate outcome of process and GSK's offer.

-GSK's tender offer will expire after July 16, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on April 19 after GSK made a private proposal on April 11.

-GSK believes the three months that will have passed since the start of this process is more than adequate time for the HGS Board to bring it to completion.

-Based on circumstances at that time, GSK will consider all available options regarding its offer but can make no assurance that the tender offer will be further extended.

-As GSK has clearly stated, the company remains willing to meet and review its offer with HGS at any time.

-Shares at 1104 GMT down 1%, at 1438 pence, valuing the company at GBP72 billion.

-Write to Mark Shapland at mark.shapland@dowjones.com

Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Human Genome Sciences Charts.
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Human Genome Sciences Charts.